We are live on ! Find out more

MeiraGTx Holdings

MGTX

Market cap $911M

9.49 USD

-0.22

2.27%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

9.49

0.00

0%

1 day

-2.27%

5 days

2.71%

1 month

-13.73%

3 months

-20.78%

6 months

2.93%

Year to date

21.51%

1 year

8.71%

5 years

-53.93%

10 years

-36.73%

About: MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Employees: 393

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 85.7%

Negative 0%

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy. GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

Zacks Investment Research

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital to support development and commercialization of AAV2-hAQP1 and bota-vec Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mid-2027 LONDON and NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update. “During the second quarter of 2026, we made tremendous progress towards transforming MeiraGTx into a commercial company,” said Alexandria Forbes, Ph.D.

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards under the Company's 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Some Potential Merit Within MeiraGTx Holdings

MeiraGTx Holdings plc is positioned potentially for significant upside with late-stage gene therapy assets targeting large, high-unmet-need indications. AAV2-hAQP1 for radiation-induced xerostomia could address a $3.7B peak sales market with no direct competition; pivotal Phase 2 data expected 2Q27. Robust optionality from GAD for Parkinson's, bota-vec for XLRP, milestone payments, and the innovative Riboswitch platform enhances MGTX's valuation case.

Some Potential Merit Within MeiraGTx Holdings

Zacks Investment Research

Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?

The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?

The Motley Fool

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity holdings in the company.

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

See News Rankings

Price charts implemented using Lightweight Charts™